An economic evaluation of two ototopical treatments for acute otitis media in tympanostomy tube patients

Peter S. Roland, Curtis R. Waycaster, G. Michael Wall, Jeffrey D. Glass

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: The goal of this research was to determine the cost-effectiveness of ciprofloxacin 0.3%/dexamethasone 0.1% (CD) otic suspension versus ofloxacin 0.3% otic solution (OFX) for treatment of acute otitis media in tympanostomy tube patients. Methods: A decision-analytic model was used to emulate the ototopical treatment of acute otitis media in patients with tympanostomy tubes. The economic outcome was the cost per otorrhea-free day (OFD) achieved per episode of care. Three tiers of antimicrobial therapy were modeled, with each successive tier representing the retreatment of clinical failures from the preceding tier. First-tier therapy compared CD and OFX using outcome measures obtained from a randomized clinical trial (n = 599). Second-tier therapy modeled the use of amoxicillin/clavulanate (ACA) using outcome measures obtained from a physician survey and medical literature. Third-tier therapy was modeled as pathogen-specific and curative. It could follow one of three pathways: 1) intramuscular ceftriaxone; 2) oral fluconazole; or 3) hospitalization for intravenous antibiotics. Third-tier outcomes were based on a physician survey. Cost data were obtained from standard references and presented from a payer perspective. Results: The expected therapeutic costs were $249.40 for the CD pathway and $265.44 for the OFX pathway. The estimated number of OFDs per episode of care was 25.88 for the CD pathway and 23.86 for the OFX pathway. The cost-effectiveness ratios for CD and OFX therapies were $9.64 and $11.13 per OFD, respectively. Conclusion: CD is both more effective and less costly than OFX for the treatment of acute otitis media in patients with tympanostomy tubes.

Original languageEnglish (US)
Pages (from-to)219-226
Number of pages8
JournalValue in Health
Volume9
Issue number4
DOIs
StatePublished - Jul 2006

Fingerprint

Middle Ear Ventilation
Otitis Media
Cost-Benefit Analysis
Ciprofloxacin
Dexamethasone
costs
evaluation
economics
Episode of Care
physician
Therapeutics
Costs and Cost Analysis
Ear
hospitalization
Outcome Assessment (Health Care)
Physicians
Clavulanic Acid
Retreatment
Ofloxacin
Ceftriaxone

Keywords

  • Ciprofloxacin
  • Cost-effectiveness
  • Decision analysis
  • Dexamethasone
  • Ofloxacin
  • Otorrhea
  • Tympanostomy

ASJC Scopus subject areas

  • Nursing(all)
  • Health(social science)
  • Health Professions(all)

Cite this

An economic evaluation of two ototopical treatments for acute otitis media in tympanostomy tube patients. / Roland, Peter S.; Waycaster, Curtis R.; Wall, G. Michael; Glass, Jeffrey D.

In: Value in Health, Vol. 9, No. 4, 07.2006, p. 219-226.

Research output: Contribution to journalArticle

Roland, Peter S. ; Waycaster, Curtis R. ; Wall, G. Michael ; Glass, Jeffrey D. / An economic evaluation of two ototopical treatments for acute otitis media in tympanostomy tube patients. In: Value in Health. 2006 ; Vol. 9, No. 4. pp. 219-226.
@article{44bc2aa822b94a09a3ee2723070e4fa8,
title = "An economic evaluation of two ototopical treatments for acute otitis media in tympanostomy tube patients",
abstract = "Objective: The goal of this research was to determine the cost-effectiveness of ciprofloxacin 0.3{\%}/dexamethasone 0.1{\%} (CD) otic suspension versus ofloxacin 0.3{\%} otic solution (OFX) for treatment of acute otitis media in tympanostomy tube patients. Methods: A decision-analytic model was used to emulate the ototopical treatment of acute otitis media in patients with tympanostomy tubes. The economic outcome was the cost per otorrhea-free day (OFD) achieved per episode of care. Three tiers of antimicrobial therapy were modeled, with each successive tier representing the retreatment of clinical failures from the preceding tier. First-tier therapy compared CD and OFX using outcome measures obtained from a randomized clinical trial (n = 599). Second-tier therapy modeled the use of amoxicillin/clavulanate (ACA) using outcome measures obtained from a physician survey and medical literature. Third-tier therapy was modeled as pathogen-specific and curative. It could follow one of three pathways: 1) intramuscular ceftriaxone; 2) oral fluconazole; or 3) hospitalization for intravenous antibiotics. Third-tier outcomes were based on a physician survey. Cost data were obtained from standard references and presented from a payer perspective. Results: The expected therapeutic costs were $249.40 for the CD pathway and $265.44 for the OFX pathway. The estimated number of OFDs per episode of care was 25.88 for the CD pathway and 23.86 for the OFX pathway. The cost-effectiveness ratios for CD and OFX therapies were $9.64 and $11.13 per OFD, respectively. Conclusion: CD is both more effective and less costly than OFX for the treatment of acute otitis media in patients with tympanostomy tubes.",
keywords = "Ciprofloxacin, Cost-effectiveness, Decision analysis, Dexamethasone, Ofloxacin, Otorrhea, Tympanostomy",
author = "Roland, {Peter S.} and Waycaster, {Curtis R.} and Wall, {G. Michael} and Glass, {Jeffrey D.}",
year = "2006",
month = "7",
doi = "10.1111/j.1524-4733.2006.00105.x",
language = "English (US)",
volume = "9",
pages = "219--226",
journal = "Value in Health",
issn = "1098-3015",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - An economic evaluation of two ototopical treatments for acute otitis media in tympanostomy tube patients

AU - Roland, Peter S.

AU - Waycaster, Curtis R.

AU - Wall, G. Michael

AU - Glass, Jeffrey D.

PY - 2006/7

Y1 - 2006/7

N2 - Objective: The goal of this research was to determine the cost-effectiveness of ciprofloxacin 0.3%/dexamethasone 0.1% (CD) otic suspension versus ofloxacin 0.3% otic solution (OFX) for treatment of acute otitis media in tympanostomy tube patients. Methods: A decision-analytic model was used to emulate the ototopical treatment of acute otitis media in patients with tympanostomy tubes. The economic outcome was the cost per otorrhea-free day (OFD) achieved per episode of care. Three tiers of antimicrobial therapy were modeled, with each successive tier representing the retreatment of clinical failures from the preceding tier. First-tier therapy compared CD and OFX using outcome measures obtained from a randomized clinical trial (n = 599). Second-tier therapy modeled the use of amoxicillin/clavulanate (ACA) using outcome measures obtained from a physician survey and medical literature. Third-tier therapy was modeled as pathogen-specific and curative. It could follow one of three pathways: 1) intramuscular ceftriaxone; 2) oral fluconazole; or 3) hospitalization for intravenous antibiotics. Third-tier outcomes were based on a physician survey. Cost data were obtained from standard references and presented from a payer perspective. Results: The expected therapeutic costs were $249.40 for the CD pathway and $265.44 for the OFX pathway. The estimated number of OFDs per episode of care was 25.88 for the CD pathway and 23.86 for the OFX pathway. The cost-effectiveness ratios for CD and OFX therapies were $9.64 and $11.13 per OFD, respectively. Conclusion: CD is both more effective and less costly than OFX for the treatment of acute otitis media in patients with tympanostomy tubes.

AB - Objective: The goal of this research was to determine the cost-effectiveness of ciprofloxacin 0.3%/dexamethasone 0.1% (CD) otic suspension versus ofloxacin 0.3% otic solution (OFX) for treatment of acute otitis media in tympanostomy tube patients. Methods: A decision-analytic model was used to emulate the ototopical treatment of acute otitis media in patients with tympanostomy tubes. The economic outcome was the cost per otorrhea-free day (OFD) achieved per episode of care. Three tiers of antimicrobial therapy were modeled, with each successive tier representing the retreatment of clinical failures from the preceding tier. First-tier therapy compared CD and OFX using outcome measures obtained from a randomized clinical trial (n = 599). Second-tier therapy modeled the use of amoxicillin/clavulanate (ACA) using outcome measures obtained from a physician survey and medical literature. Third-tier therapy was modeled as pathogen-specific and curative. It could follow one of three pathways: 1) intramuscular ceftriaxone; 2) oral fluconazole; or 3) hospitalization for intravenous antibiotics. Third-tier outcomes were based on a physician survey. Cost data were obtained from standard references and presented from a payer perspective. Results: The expected therapeutic costs were $249.40 for the CD pathway and $265.44 for the OFX pathway. The estimated number of OFDs per episode of care was 25.88 for the CD pathway and 23.86 for the OFX pathway. The cost-effectiveness ratios for CD and OFX therapies were $9.64 and $11.13 per OFD, respectively. Conclusion: CD is both more effective and less costly than OFX for the treatment of acute otitis media in patients with tympanostomy tubes.

KW - Ciprofloxacin

KW - Cost-effectiveness

KW - Decision analysis

KW - Dexamethasone

KW - Ofloxacin

KW - Otorrhea

KW - Tympanostomy

UR - http://www.scopus.com/inward/record.url?scp=33746392774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746392774&partnerID=8YFLogxK

U2 - 10.1111/j.1524-4733.2006.00105.x

DO - 10.1111/j.1524-4733.2006.00105.x

M3 - Article

C2 - 16903991

AN - SCOPUS:33746392774

VL - 9

SP - 219

EP - 226

JO - Value in Health

JF - Value in Health

SN - 1098-3015

IS - 4

ER -